TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.-MedSci.cn

TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.

Rini, BI; Pal, SK; Escudier, B; Atkins, MB; Hutson, TE; Porta, C; Verzoni, E; Needle, MN; McDermott, DF

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务